Neuroprotective agents that slow cell death, vital for the treatment of a range of neurodegenerative disorders, are currently lacking. Dragunow discusses some of the factors contributing to the failure of translation from the laboratory to the clinic, and suggests approaches to introduce an adult human preclinical platform to overcome translation obstacles in neurodegenerative drug development.
